FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

CIPLA

765.3
-12.35 (-1.59%)
Updated 03:29 23/09 IST

CIPLA Buy or Sell - FrontPage Forums

1 Users have submitted 1 trade ideas of Rs. 33,000 for CIPLA
Disclaimer
100% Bullish
0% Bearish

CIPLA Buy or Sell - Brokerage Reports

No. of reports in last year
9
No. of analysts
7
Average Consensus Forecast
536.44
Consensus Potential
-46.90%
See CIPLA Share Price Targets >>

CIPLA Ratings

Long term CIPLA rating by FrontPage users
3.9/5 (9 Ratings)
Find answers to all your questions on live CIPLA message board: Is CIPLA buy or sell? Should I buy CIPLA shares? Why are CIPLA shares falling? Should I invest in CIPLA stock?

  1. Home
  2. CIPLA Forum

CIPLA Share Price Discussion

B
Reputation: -15,320 • Yesterday 4:08 AM

Type
Buy
Instrument
CIPLA SEP20 FUT
Entry Price
₹778.2
Price@Trade
₹778.2
Target Price
₹790
Stop Price
₹774
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹470,039.05 approx for 1300 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
NIFTY 24SEP20 11300 CE
Entry Price
₹25
Price@Trade
₹25.65
Target Price
₹60
Stop Price
₹0
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹75,000 approx for 3000 Qty
Status
Waiting for entry
Like
Reply
N
Reputation: 6,112 • Yesterday 4:08 AM
Majeso hits 52-week high as UNIFI Wealth Management buys 2 lakh shares in bulk deal
According to bulk deal data available on NSE, UNIFI Wealth Management bought 2,06,000 shares of the company at an average price of Rs 779.05 per share.
Moneycontrol
Like
Reply

Type
Buy
Instrument
BANKNIFTY 24SEP20 21000 PE
Entry Price
₹90
Price@Trade
₹89.3
Target Price
₹160
Stop Price
₹75
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹2,250 approx for 25 Qty
Status
Active
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Yesterday 4:08 AM

Update
Trade Entered
Entry Price
₹90

Type
Buy
Instrument
BHARTIARTL
Entry Price
₹442
Price@Trade
₹449.8
Target Price
₹444
Stop Price
₹440
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹442,000 approx for 1000 Qty
Status
Waiting for entry
Like
Reply

Type
Buy
Instrument
BANKNIFTY 24SEP20 21100 CE
Entry Price
₹300
Price@Trade
₹284.35
Target Price
₹450
Stop Price
₹220
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹75,000 approx for 250 Qty
Status
Waiting for entry
Like
Reply
K
Reputation: -287 • Yesterday 4:06 AM

Type
Buy
Instrument
NATURALGAS 25SEP20 FUT
Entry Price
₹136.5
Price@Trade
₹135.1
Target Price
₹138
Stop Price
₹135
Valid Till
Sep 23, 2020 11:20 AM
Margin
₹49,610.94 approx for 1250 Qty
Status
Waiting for entry
Like
Reply

Type
Buy
Instrument
BANKNIFTY 24SEP20 21600 CE
Entry Price
₹65  ₹63.45
Price@Trade
₹66.8
Target Price
₹120
Stop Price
₹50
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹1,269,000 approx for 20000 Qty
Status
Waiting for entry
Like
Reply (1)
See all replies

Update
Entry Price Modified
Price @ Update
₹63.45
Original Entry Price
₹65
New Entry Price
₹63.45
P
Reputation: -883 • Yesterday 4:06 AM

Type
Buy
Instrument
IBULHSGFIN
Entry Price
₹156.4
Price@Trade
₹156.4
Target Price
₹210
Stop Price
₹105
Valid Till
Sep 30, 2020 3:20 AM
Margin
₹15,640 approx for 100 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
BANKNIFTY 24SEP20 21200 CE
Entry Price
₹222.6
Price@Trade
₹222.6
Target Price
₹300
Stop Price
₹210
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹556,500 approx for 2500 Qty
Status
Active
Like
Reply

HDFCAMC - chart - 1356855
Technical View # HDFC AMC LTP 2221/-Rs
Final Target Price 2725/-Rs
Long Term investors can start accumulation
Disclaimers: - The contents produced here are purely for Educational Purposes. They Should Not Be Constructed as Buy/Sell Recommendations
Financial Interes...
Read more...
Like
Reply
N
Reputation: 6,112 • Yesterday 4:06 AM
Private banks, IT stocks dominate Jefferies’ 19-stock India model portfolio
“…we believe it's a buy-on-dips market. This constructive view is predicated on continued global liquidity (hence depressed risk-free rate, justifying valuations) and encouraging economic recovery trend,” Jefferies analysts Mahesh Nandurkar and Anubhav Sinha said in a note on Tuesday.
The Economic Times
Like
Reply
K
Reputation: 210,136 • Yesterday 4:05 AM

Type
Buy
Instrument
ADANIENT SEP20 295 CE
Entry Price
₹5
Price@Trade
₹5
Target Price
₹8
Stop Price
₹4
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹1,000,000 approx for 200000 Qty
Status
Active
Like
Reply
C
Reputation: 2,478 • Yesterday 4:05 AM

Type
Buy
Instrument
CRUDEOIL 19OCT20 FUT
Entry Price
₹2,900
Price@Trade
₹2,902
Target Price
₹2,950
Stop Price
₹2,850
Valid Till
Sep 23, 2020 11:20 AM
Margin
₹295,627.5 approx for 100 Qty
Status
Waiting for entry
Like
Reply

Type
Buy
Instrument
BANKNIFTY 24SEP20 21200 CE
Entry Price
₹225
Price@Trade
₹226.5
Target Price
₹240
Stop Price
₹210
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹450,000 approx for 2000 Qty
Status
Exited before entry
Like
Reply (1)
See all replies
Shantanu @shantanudethe
Yesterday 4:05 AM

Update
Exited before entry
Price @ Update
₹222.65

Type
Buy
Instrument
CUMMINSIND
Entry Price
₹455
Price@Trade
₹458.2
Target Price
₹495
Stop Price
₹447
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹113,750 approx for 250 Qty
Status
Waiting for entry
Like
Reply

Type
Buy
Instrument
ITC SEP20 177.35 CE
Entry Price
₹1.35
Price@Trade
₹1.35
Target Price
₹3.9
Stop Price
₹0.7
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹86,400 approx for 64000 Qty
Status
Active
Like
Reply
R
Reputation: 4,205 • Yesterday 4:05 AM

Type
Sell
Instrument
GOLD 05OCT20 FUT
Entry Price
₹50,000
Price@Trade
₹49,906
Target Price
₹49,700
Stop Price
₹50,300
Valid Till
Sep 23, 2020 11:20 AM
Margin
₹364,682.5 approx for 100 Qty
Status
Waiting for entry
Like
Reply
K
Reputation: -287 • Yesterday 4:04 AM

Type
Sell
Instrument
ALUMINIUM 30SEP20 FUT
Entry Price
₹143.5
Price@Trade
₹143.9
Target Price
₹142
Stop Price
₹145
Valid Till
Sep 30, 2020 11:20 AM
Margin
₹68,993.75 approx for 5000 Qty
Status
Waiting for entry
Like
Reply
R
Reputation: -47,031 • Yesterday 4:04 AM

Type
Buy
Instrument
NIFTY 24SEP20 11200 PE
Entry Price
₹46.55
Price@Trade
₹46.55
Target Price
₹400
Stop Price
₹0
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹55,860 approx for 1200 Qty
Status
Active
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • CIPLA - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization42,645.7
    Enterprise Value42,471.14
    Price to Earnings29.77
    Price to Book Value2.7
    Return on Capital Employed0.13
    Return on Equity0.1
    Face Value2
    Dividend Yield0.01
  • CIPLA - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    18-May-20Nirmal BangAccumulate575
    16-May-20HDFC SecuritiesBuy655
    16-May-20Prabhudas LilladherReduce542
    9-Apr-20HDFC SecuritiesBuy600
    6-Feb-20Motilal OswalNeutral490
    CIPLA Brokerage Price Target
  • CIPLA Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Sep 23783.95784761.8767.4
    Sep 21806.25811.95762768.1
    Sep 18780819.3776.15806.25
    Sep 17751762746.7751.5
    Sep 16743.95756.5732752.6
  • CIPLA Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹740.98
    30 Day Moving Average₹748.15
    50 Day Moving Average₹724.38
    100 Day Moving Average₹674.93
    200 Day Moving Average₹570.73
  • CIPLA - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue11,39010,974.580.04
    Operating Profit2,1181,596.260.33
    Profit Before Tax1,9111,186.940.61
    Net Income1,469974.940.51
  • CIPLA - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds15,78214,1140.12
    Total Liabilities2,6373,497-0.25
    Total Assets18,41917,6100.05
  • CIPLA - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1,1172,205.56-0.49
    Cash from Investing Activity-593-1,191.75-0.5
    Cash from Financing Activity-351-1,008.97-0.65
    Net Cash Flow1734.8434.74
  • CIPLA - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.080.06
    Return on Equity0.10.08
    Return on Capital Employed0.130.09
  • CIPLA - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.12
    3 Year CAGR Growth in Operating Profit0.08
    3 Year CAGR Growth in EBIDTA0.16
    3 Year CAGR Growth in Net Income0.24
    3 Yr CAGR Growth - Diluted EPS0.24
  • CIPLA - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.39
    5 Year CAGR Growth in Operating ProfitNA
    5 Year CAGR Growth in EBIDTA0.05
    5 Year CAGR Growth in Net Income-0.03
    3 Yr CAGR Growth - Diluted EPS-0.03
  • CIPLA - Recent News

    keyboard_arrow_down
    NewsBot
    Sep 22 12:26 PM
    Day trading guide for Wednesday's market
    The Economic Times
    NewsBot
    Sep 19 9:51 AM
    Both IT and pharma are in the midst of a bull run: Sudip Bandyopadhyay
    The Economic Times
    NewsBot
    Sep 18 10:26 AM
    F&O: Nifty seems to be consolidating with upside capped; VIX eases more
    The Economic Times
    NewsBot
    Sep 18 8:36 AM
    Cipla, Lupin may gain from Perrigo's drug recall, says Macquarie
    The Economic Times
    NewsBot
    Sep 18 7:36 AM
    API CDMOs and complex generics offer best bets in pharma: Ravi Dharamshi
    The Economic Times
    NewsBot
    Sep 18 6:11 AM
    Stock market news: Cipla shares up soars over 7%
    The Economic Times
    NewsBot
    Sep 18 4:58 AM
    Lupin shares hit 52-week high, Cipla shares jump 6% after Perrigo recalls albuterol sulfate
    Moneycontrol
    NewsBot
    Sep 17 7:46 AM
    LIVE Market Technicals with CK Narayan
    The Economic Times
    NewsBot
    Sep 8 2:43 AM
    Medicine sales decline in August after two months: Report
    Moneycontrol
    NewsBot
    Sep 2 6:31 AM
    Why a bull market in Covid-damaged sectors is likely in 1-3 years
    The Economic Times
  • CIPLA - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
    Apollo Hospitals Enterprise Ltd. NSE:...
  • CIPLA - More Information

    keyboard_arrow_down

    Cipla Ltd:
    Cipla Limited, along with its multiple subsidiaries, is responsible for the manufacture and sale of pharmaceutical goods in India. It provides a variety of formulations and active pharmaceutical ingredients in various aspects like urology, ophthalmology, malaria, oncology, neurosciences, women’s and children’s health, hepatitis, critical care, osteoporosis, and infectious diseases.
    The company provides multiple inhalation therapy devices like nasal sprays, metered-dose inhalers, accessory devices, dry powder inhalers, and nebulizers. Apart from manufacturing and selling these products in India, it also exports to Russia, the Middle East, Asia, Australia, New Zealand, and Latin America and other regions internationally.
    On 17th of August in 1935, Cipla got registered as a public limited with a capital of Rs. 6 lakh and is a Mumbai based Company in India. During the Second World War, when the drug supplies were topped in 1941, the company started to produce fine chemicals. At this point, Cipla dedicated its facilities to provide a variety of ingenious drugs.
    About Company Information:
    Within the next two decades after the inception of the Second World War, in 1960, the company started its operations in Vikhroli, Mumbai. This was their second plant. At this unit, they produced fine chemicals related to natural products. Ampicillin was manufactured for the first time in the country in 1968 by Cipla. To cultivate medicinal plants, the company then started their Agricultural Research Division, located in Bangalore, in the year 1972.
    In 1982, the company started operating in its fourth manufacturing unit located in Patalganga, Maharashtra. The company collaborated with the National Chemical Laboratory in Pune, in the year 1984 to produce anti-cancer drugs like vincristine and vinblastine. Collaborating with Indian Institute of Chemical Technology, in 1991, a drug considered to be a breakthrough in chemotherapy, named etoposide was launched by the company. Later on, an antiretroviral drug called zidovudine was also manufactured by the company in association with Indian Institute of Chemical Technology.
    Nevirapine, an antiretroviral drug used to stop AIDS transmission in a child from a mother, was launched by the company in 1999. Cipla was the first company, outside of Europe and U.S.A, which began CFC-free-inhalers, in the year 2000. In February in 2007, the company allied with the Drugs for Neglected Diseases Initiative for developing a new anti-malarial drug. This was a worldwide initiative taken by the company with a non-profit organization like DNDI.
    In April of 2010, the company started its operations for commercial production of a variety of pharmaceutical formulations at their SEZ project in Indore, MP. On the 21st of July, 2012, Cipla revealed that they were to collaborate with DNDi (a non-profit R&D organization) for developing an improved form of antiretroviral (ARV) combo therapy which will specifically treat kids affected by HIV/AIDS.
    On the 17th of April, 2013, Cipla announced that they would be the first to launch a biosimilar of Etanercept in the country which will be targeted to treat rheumatic disorders. On the 20th of February in 2014, Cipla announced their alliance with MSD which would give them a non-exclusive license using which they would sell raltegravir 400mg tablet (a drug from MSD) along with marketing and distribution of the drug but down under a different brand name.
    In February 2015, Cipla revealed to have been awarded a Global Fund ARV Tender which is worth USD 188.95 million for developing antiretroviral drugs.
    On the 12th of October, 2016, Cipla announced the formal closing of US FDA inspection that was conducted in July-August in the year 2015. Cipla was given the establishment inspection report by the FDA, and it was held AT THE Indore Unit of the company. On the 30th of November, 2017, Cipla publicized the fact that the company had received approval from the World Health Organization (WHO) for a product name Q-TIB, which is essentially a combination of novel fixed-dose within a single tablet form. This was the first combination to ever exist in the world.
    How Cipla Ltd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Cipla Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Cipla Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020